ES3042412T3 - Azaquinolines as inhibitors of cd38 - Google Patents

Azaquinolines as inhibitors of cd38

Info

Publication number
ES3042412T3
ES3042412T3 ES22704226T ES22704226T ES3042412T3 ES 3042412 T3 ES3042412 T3 ES 3042412T3 ES 22704226 T ES22704226 T ES 22704226T ES 22704226 T ES22704226 T ES 22704226T ES 3042412 T3 ES3042412 T3 ES 3042412T3
Authority
ES
Spain
Prior art keywords
alkyl
nrc3rd3
nrcrd
haloalkyl
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES22704226T
Other languages
English (en)
Spanish (es)
Inventor
Jennifer Downing
Kevin Wayne Kuntz
Laurie B Schenkel
Melissa Marie Vasbinder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES3042412T3 publication Critical patent/ES3042412T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES22704226T 2021-01-29 2022-01-28 Azaquinolines as inhibitors of cd38 Active ES3042412T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163143245P 2021-01-29 2021-01-29
PCT/US2022/014221 WO2022165114A1 (en) 2021-01-29 2022-01-28 Quinolines and azaquinolines as inhibitors of cd38

Publications (1)

Publication Number Publication Date
ES3042412T3 true ES3042412T3 (en) 2025-11-20

Family

ID=80446310

Family Applications (1)

Application Number Title Priority Date Filing Date
ES22704226T Active ES3042412T3 (en) 2021-01-29 2022-01-28 Azaquinolines as inhibitors of cd38

Country Status (25)

Country Link
US (2) US11952377B2 (https=)
EP (2) EP4674415A3 (https=)
JP (2) JP7777596B2 (https=)
KR (1) KR20230141799A (https=)
CN (1) CN117580829A (https=)
AR (1) AR124718A1 (https=)
AU (1) AU2022212035A1 (https=)
BR (1) BR112023014898A2 (https=)
CA (1) CA3208851A1 (https=)
CL (2) CL2023002163A1 (https=)
CO (1) CO2023009803A2 (https=)
CR (1) CR20230323A (https=)
DO (1) DOP2023000142A (https=)
EC (1) ECSP23056223A (https=)
ES (1) ES3042412T3 (https=)
HR (1) HRP20251111T1 (https=)
HU (1) HUE072981T2 (https=)
IL (1) IL304466A (https=)
JO (1) JOP20230160A1 (https=)
MX (1) MX2023008701A (https=)
PE (1) PE20232047A1 (https=)
PL (1) PL4284511T3 (https=)
RS (1) RS67253B1 (https=)
TW (1) TW202241418A (https=)
WO (1) WO2022165114A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021021986A1 (en) 2019-07-31 2021-02-04 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of cd38
WO2024217995A1 (en) 2023-04-20 2024-10-24 Syngenta Crop Protection Ag Pesticidally active dihydropyridinone derivatives
WO2026000074A1 (en) * 2024-06-25 2026-01-02 Welnx Company Inc. Use of cd38 inhibitors for reducing th2 inflammation
WO2026075971A1 (en) 2024-10-01 2026-04-09 Neolaia Inc. Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors
CN119775288B (zh) * 2024-12-31 2025-10-10 浙江工业大学 一种cd38抑制化合物及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2607064T3 (es) 2010-12-01 2017-03-29 Glaxosmithkline Llc Indoles
BR112014010803A2 (pt) 2011-11-04 2017-04-25 Glaxosmithkline Intellectual Property (No 2) Ltd método de tratamento
JP6464139B2 (ja) * 2013-03-14 2019-02-06 コンバージーン・リミテッド・ライアビリティ・カンパニーConvergene Llc ブロモドメイン含有タンパク質の阻害のための方法および組成物
AU2015356721B2 (en) 2014-12-03 2018-03-15 Glaxosmithkline Intellectual Property (No.2) Limited CD38 inhibitors and methods of treatment
WO2017053604A1 (en) 2015-09-23 2017-03-30 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
EP3434692A1 (en) 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
WO2021021986A1 (en) 2019-07-31 2021-02-04 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of cd38
US20230025807A1 (en) 2019-10-30 2023-01-26 Mitobridge Inc. Cd38 inhibitors
BR112022020291A2 (pt) 2020-04-07 2022-12-06 Mitobridge Inc Inibidores de cd38

Also Published As

Publication number Publication date
CN117580829A (zh) 2024-02-20
IL304466A (en) 2023-09-01
AU2022212035A1 (en) 2023-08-03
CL2024001535A1 (es) 2024-11-04
DOP2023000142A (es) 2023-08-31
AU2022212035A9 (en) 2025-03-06
BR112023014898A2 (pt) 2023-10-31
US11952377B2 (en) 2024-04-09
AR124718A1 (es) 2023-04-26
RS67253B1 (sr) 2025-10-31
EP4284511C0 (en) 2025-07-16
EP4284511B1 (en) 2025-07-16
JOP20230160A1 (ar) 2023-07-20
KR20230141799A (ko) 2023-10-10
JP2024506814A (ja) 2024-02-15
JP7777596B2 (ja) 2025-11-28
CR20230323A (es) 2023-10-02
PL4284511T3 (pl) 2025-12-22
EP4674415A3 (en) 2026-03-04
WO2022165114A1 (en) 2022-08-04
HRP20251111T1 (hr) 2025-11-21
JP2025160175A (ja) 2025-10-22
EP4284511A1 (en) 2023-12-06
EP4674415A2 (en) 2026-01-07
PE20232047A1 (es) 2023-12-27
US20220242862A1 (en) 2022-08-04
ECSP23056223A (es) 2023-11-30
CO2023009803A2 (es) 2023-10-09
CA3208851A1 (en) 2022-08-04
HUE072981T2 (hu) 2025-12-28
TW202241418A (zh) 2022-11-01
MX2023008701A (es) 2023-11-29
US20240279224A1 (en) 2024-08-22
CL2023002163A1 (es) 2024-01-05

Similar Documents

Publication Publication Date Title
US11987584B2 (en) Heterobicyclic amides as inhibitors of CD38
ES3042412T3 (en) Azaquinolines as inhibitors of cd38
ES2757948T3 (es) Compuestos heterocíclicos como inhibidores LSD1
ES2718218T3 (es) Derivados de 4,5,6,7-tetrahidropirazolo[1,5-a]pirazina sustituidos como inhibidores de caseína cinasa 1 D/E
EP2074122B1 (en) Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
AU2017289315B2 (en) Heteroaromatic derivatives as NIK inhibitors
HK40129150A (en) Azaquinolines as inhibitors of cd38
EA049932B1 (ru) Хинолины и азахинолины в качестве ингибиторов cd38
EA048196B1 (ru) Гетеробициклические амиды как ингибиторы cd38
EA051811B1 (ru) Гетеробициклические амиды как ингибиторы cd38
HK1216316A1 (en) Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
HK1216316B (en) Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors